SecBot SecBot

SCNX

Scienture Holdings, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001382574 Biotech & Drug Discovery
$3.14 +0.21 (+7.34%)
Oct 27 4:00 PM ET · prev $2.93
Market cap
$4.7M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$6.00
+91% · range $6.00–6.00
1 year
−88.7%
from $27.75 · Oct 27
30 days
−53.4%
from $6.75
52-week range
$2.77–27.75
−89% from high · low Oct 22
Avg volume 20D
409.8K
Oct 2 spike 6.54M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/4
Strongest BULLISH Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2 2026's…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 3 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$2.000 → −$1.570 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    54% below its 50-day average. New closing low $2.77 on Oct 22.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 1.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD510,391$178.6K
NORTHERN TRUST CORPDOUBLED87,606$30.7K
JANE STREET GROUP, LLCDOUBLED75,729$26.5K
GEODE CAPITAL MANAGEMENT, LLCADD432,186$123.2K
UBS Group AGTRIM107,833$30.7K
CITIGROUP INCDOUBLED5,547$1.6K
VANGUARD GROUP INCDOUBLED606,151$309.1K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED316,201$161.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 1 analysts

Price is below the lowest target. Median implies +91%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 23, 2026Maxim Group
MAINTAIN
MAINTAINBuy
Reddit
Recent posts
r/pennystocks Neutral 26d ago
02 OCT 2026 , WHAT ARE THE BIGGEST LOSERS AND WHY ?
1 upvotes · 1 comments
All social signals and their track records

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Feb 20, 2026
Narasimhan Mani
President & Co-CEO
AWARD500,000 sh
Feb 20, 2026
Shankar Hariharan
Co-CEO & Chairman
AWARD500,000 sh
Oct 1, 2025
Narasimhan Mani
President & Co-CEO
AWARD300,000 sh
Oct 1, 2025
Shankar Hariharan
Co-CEO & Chairman
AWARD300,000 sh
Apr 14, 2025
Shankar Hariharan
Co-CEO & Chairman
AWARD750,000 sh
Apr 14, 2025
Narasimhan Mani
President & Co-CEO
AWARD750,000 sh
Mar 10, 2025
Shankar Hariharan
Co-CEO & Chairman
OTHER30,000 sh
Mar 10, 2025
Narasimhan Mani
President & Co-CEO
OTHER20,000 sh

Earnings setup

Estimates
−$1.57
EPS estimate, this quarter
+21%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.57-$1.57–-$1.57-4.7%$0.00
Next Q-$0.37-$0.37–-$0.37+50.7%$2.0M
Current FY-$4.44-$4.44–-$4.44+22.8%$3.6M
Next FY-$0.27-$0.27–-$0.27—$15.5M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Oct 2, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2's $344K, driven by…
PRESS-RELEASE — Impact 5/10
Oct 22, 2026 Earnings
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Milli
Oct 19, 2026 SEC
Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2 2026's ~$344K, driven…
8-K — Impact 6/10
Oct 13, 2026 SEC
Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, a 256% sequential increase from Q2 2026's $344K…
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
510,391 shares ($178.6K)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — DOUBLED
87,606 shares ($30.7K)
Feb 20, 2026 Insider
Narasimhan Mani was granted 500,000 shares
President & Co-CEO
Feb 20, 2026 Insider
Shankar Hariharan was granted 500,000 shares
Co-CEO & Chairman
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 22, 2026
Earnings
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and…
Oct 20, 2026
Listing
Listing Status: SCNX — Normal (was Deficient)
Scienture Holdings, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Oct 13, 2026
Earnings
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant…
Oct 5, 2026
Trading halt
Halt Resumed: SCNX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-02T23:50:00.000Z | Resumed 2026-10-05T13:00:00.000Z
Oct 2, 2026
Trading halt
Trading Halt: SCNX — T1 (News Pending)
Scienture Hldgs Inc Cmn | Market: NASDAQ | Code: T1 — News Pending

SecBot reports

9 filings · 2 bullish · 2 bearish · 1 mixed · 4 neutral
All SCNX filing & press-release reports (9)